Adherex Technologies Inc.
TSX : AHX
AMEX : ADH

Adherex Technologies Inc.

October 23, 2007 08:30 ET

Adherex to Participate in Windhover's Therapeutic Area Partnerships Meeting

RESEARCH TRIANGLE PARK, NORTH CAROLINA--(Marketwire - Oct. 23, 2007) - Adherex Technologies Inc. (TSX:AHX)(AMEX:ADH), a biopharmaceutical company with a broad portfolio of oncology products under development, today announced that Dr. William P. Peters, Adherex's Chairman and CEO, will be participating in Windhover Information's Therapeutic Area Partnerships Meeting on Thursday, October 25, 2007 at 1 pm ET at the Loews Philadelphia Hotel. ADH-1 was selected by Windhover Information and the publishers of In Vivo and Startup as one of the top 10 most interesting oncology projects available for partnering. The criteria for the top 10 selections included:

- Large market, large unmet need, with increasing opportunity

- History of the molecule and drug

- Strong science

- Strong company

- Diversity of indications

- Potential for new opportunities beyond the initial indications

- Multi-level partnering opportunities

ADH-1 has been well tolerated in four Phase I and Phase II clinical trials as a single-agent, with evidence of anti-tumor activity, and is currently enrolling patients in two Phase I clinical trials in combination with chemotherapy after significant synergy was observed in preclinical models. The first combination trial is testing systemic ADH-1 in combination with isolated limb infusion (ILI) melphalan for the treatment of melanoma. The second combination trial is testing systemic ADH-1 in combination with three separate systemic chemotherapy agents (docetaxel, capecitabine or carboplatin). Both trials are nearing completion of patient accrual and final data will be presented at an appropriate scientific venue once available.

About Adherex Technologies

Adherex Technologies Inc. is a biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics. We aim to be a leader in developing innovative treatments that address important unmet medical needs in cancer. We currently have multiple products in the clinical stage of development, including eniluracil, ADH-1 and sodium thiosulfate (STS). Eniluracil, an oral dihydropyrimidine dehydrogenase (DPD) inhibitor, was previously under development by GlaxoSmithKline for oncology indications. ADH-1, our lead biotechnology compound, selectively targets N-cadherin, a protein present on certain tumor cells and established blood vessels that feed solid tumors. STS, a drug from our specialty pharmaceuticals pipeline, protects against the disabling hearing loss that can often result from treatment with platinum-based chemotherapy drugs. With a diversified portfolio of unique preclinical and clinical-stage cancer compounds and a management team with expertise in identifying, developing and commercializing novel cancer therapeutics, Adherex is emerging as a pioneering oncology company. For more information, please visit our website at www.adherex.com.

This press release may contain forward-looking statements that involve significant risks and uncertainties. The actual results, performance or achievements of the Company might differ materially from the results, performance or achievements of the Company expressed or implied by such forward-looking statements. We are subject to various risks, including the uncertainties of clinical trials, drug development and regulatory review, the early stage of our product candidates, our reliance on collaborative partners, our need for additional capital to fund our operations, our history of losses, and other risks inherent in the biopharmaceutical industry. For a more detailed discussion of related risk factors, please refer to our public filings available at www.sec.gov and www.sedar.com.

Contact Information

  • Adherex Technologies Inc.
    D. Scott Murray
    Senior Vice President, Corporate Development
    919-484-8484
    info@adherex.com